The South Korean units of McDonald's, Burger King, and KFC are facing growing skepticism over finding new owners for their franchises here, due to increased difficulties in fundraising and a growing preference among domestic consumers for healthier foods.
According to a food and beverage franchise buyout expert, the pool of buyers who can afford higher prices has become smaller because interest rate hikes have worsened the condition of the acquisition financing market.
He added that the chains' valuations will also be impacted by the concurrent sales attempts.
To avoid harsher market conditions next year, Korean fast-food franchise owners must sell their businesses this year.
Fast food restaurants face significant risks from rising labor and ingredient expenses because it is challenging to raise prices to cover these costs.
The snowballing losses in the fried chicken and hamburger business cost KFC's Korean operator KG Group, which led to a capital impairment in 2020.
KG Group is reportedly desperate to sell the KFC franchise for about 100 billion won, to secure enough cash to buy SsangYong Motor.
Following a failed attempt in 2016, McDonald's US headquarters launched another attempt to sell its Korean business.
However, prospective buyers objected to the conditions of the deal.
Operating losses for McDonald's Korea amounted to 44 billion won in 2019, 48,3 billion won in 2020, and 27.7 billion won in 2021.
The operator of Burger King's Korean location, Affinity Equity Partners, is thought to be more in need of a quick sale because it is a PEF and is required to quickly sell its portfolio companies to disperse profits to its investors.
The Hong Kong-based PEF has been attempting to sell the Burger King's Korean unit in 2016 and its Japanese counterpart for a combined 1 trillion won since late last year.
Insiders in the M&A market, however, expressed doubt about the hamburger business being purchased by a PEF and noted that it will be challenging to increase its valuation until divestiture.


Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Lee Seung-heon Signals Caution on Rate Hikes, Supports Higher Property Taxes to Cool Korea’s Housing Market
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



